Cortexyme Selects 3CLpro Inhibitor As COVID-19 Candidate

Cortexyme Inc (NASDAQ:CRTX) has selected COR803 to further evaluate for coronavirus infections, including COVID-19 disease.
COR803 is a novel patent-pending small molecule 3CLpro inhibitor, and 3CLpro (Mpro) is a validated antiviral drug target shown to be essential in viral replication of SARS-CoV-2.
The company is advancing its disease-modifying GAIN Trial in mild to moderate Alzheimer's disease, with top-line data expected in Q4 of 2021.
Price Action: CRTX shares are up 1.02% at $65.15 during the market session on the last check Friday.

To add Benzinga News as your preferred source on Google, click here.